Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn
pharmafile | June 27, 2018 | News story | Research and Development, Sales and Marketing | AbbVie, Cancer, Goggle, calico, pharma
The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development collaboration, originally signed in 2014, for another three years.
The $1.5 billion partnership has proven so successful that both Abbvie and Calico are to inject an additional $500 million each, with the latter responsible for research and early development until 2022 and pushing collaboration projects through Phase 2a until 2027. Abbvie will support Calico in these pursuits, and will be able to assume late-stage development and commercialisation in those candidates that make it past Phase 2a.
The project focuses on the development of interventions for age-related disease, including neurodegenerative conditions and cancer.
“We’ve built a successful collaboration – both scientifically and culturally – that is advancing cutting-edge science,” said Dr Michael Severino, Executive Vice President, Research and Development, Chief Scientific Officer, at AbbVie. “Calico has attracted an outstanding team of world-class scientists and the extension of this collaboration allows us to further build on the research we’ve done to identify transformative treatment options for patients with age-related diseases.”
Calico Chief Executive and former Genetech Chairman Dr Arthur D Levinson added: “Our collaboration with AbbVie has fully met our high expectations. Our initial agreement created a unique partnership and this extension will accelerate further our efforts to understand the science of aging to advance novel therapies for patients.”
Matt Fellows
Related Content
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …